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Abstract
Background—Recent studies have shown that some vaccines have beneficial effects that could 
not be explained solely by the prevention of their respective targeted disease(s).
Methods—We used the MarketScan® United States (US) Commercial Claims Databases from 
2005–2014 to assess the risk of hospital admission for non-targeted infectious diseases (NTI) in 
children from 16 through 24 months according to the last vaccine type (live and/or inactivated). 
We included children continuously enrolled within a month of birth through 15 months who 
received at least three doses of Diphtheria-Tetanus-acellular Pertussis vaccine by end of 15 months 
of age. We used Cox regression to estimate hazard ratios (HRs), stratifying by birthdate to control 
for age, year and seasonality, and adjusting for sex, chronic diseases, prior hospitalizations, 
number of outpatient visits, region of residence, urban/rural area of domicile, prematurity, low 
birth weight, and mother’s age.
Results—311,663 children were included. In adjusted analyses, risk of hospitalization for non-
targeted infections from ages 16 through 24 months was reduced for those who received live 
vaccine alone compared with inactivated alone or concurrent live and inactivated vaccines (HR 
0.50, 95% CI 0.43, 0.57 and HR 0.78, 95% CI 0.67, 0.91, respectively), and for those who 
received live and inactivated vaccines concurrently compared with inactivated only (HR 0.64, 95% 
CI 0.58, 0.70).
Conclusions—We found lower risk of non-targeted infectious disease hospitalizations from 16 
through 24 months among US children whose last vaccine received was live compared with 
inactivated vaccine, as well as concurrent receipt compared with inactivated vaccine.
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Introduction
Childhood vaccinations have been one of the greatest public health achievements in the past 
century. Vaccines are rigorously evaluated pre-licensure in clinical trials establishing their 
safety and efficacy against their targeted diseases. However, recent studies have identified 
possible nonspecific vaccine effects in children beyond their targeted infections. Studies in 
West Africa found that the measles vaccine1 and BCG vaccine2 had beneficial nonspecific 
effects that could not be explained solely by the prevention of measles and tuberculosis, 
respectively. Sorup et al in Denmark reported the first study in a high-income country that 
found receiving the live Measles-Mumps-Rubella (MMR) vaccine as the most recent vaccine 
was associated with a lower rate of admissions for infections compared with having the most 
recent the inactivated Diphtheria-Tetanus-acellular Pertussis-inactivated Polio virus-
Haemophilus influenzae type b (DTaP-IPV-Hib) vaccine by age 15 months.3
In the United States (US), the current childhood vaccination schedule recommends routine 
vaccination with live vaccines at age intervals that are similar to those for recommended 
doses of inactivated vaccines. For example, the recommended age for two of the live 
vaccines, MMR and varicella (12 to 15 months) overlaps the recommended ages for doses of 
the following inactivated vaccines: Haemophilus influenzae type b (Hib) [12 to 15 months], 
pneumococcal conjugate vaccine [12 to 15 months], Hepatitis B vaccine (HBV) [6 to 18 
months], inactivated poliovirus vaccine (IPV) [6 to 18 months], hepatitis A (HAV) [12 to 23 
months], and DTaP (15 to 18 months).
We assessed hospital admissions due to non-targeted infections (NTI) in a US population of 
children according to the type of the last vaccine received. We attempted to replicate the 
study by Sorup and colleagues3 by using similar methods to the extent possible. We also 
conducted secondary analyses to assess different types of NTIs.
Methods
Population and data source
We performed our analysis using the MarketScan® Commercial Claims Databases from 
2005–2014 (Truven Health Analytics, Ann Arbor, MI). MarketScan® collects de-identified 
individual data from commercial health insurance claims and has a wide geographical 
representation.4,5 Because no birthdate is available, we used as a proxy the diagnosis-related 
group (DRG) codes 789 through 795 for newborn hospitalization to identify subjects and 
included individuals who were enrolled in their insurance plan continuously from within a 
month of the birth hospitalization through 15 months. We defined birthdate as the date of 
admission for the newborn hospitalization. We evaluated children who had received at least 
three doses of DTaP prior to age 16 months to limit the possibility of bias attributable to 
factors related to under-vaccination.6 We excluded children enrolled in capitated insurance 
plans because of the lack of incentive among their providers to report individual claims for 
immunization services. We also excluded children who were immunosuppressed or had 
other contraindications for receiving vaccines. [See supplementary table for International 
Classification of Diseases ninth revision (ICD-9) codes] Furthermore, because influenza 
vaccination was low or nonexistent in Denmark7 during the period of the Sorup study3, we 
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excluded children who had ever received an influenza vaccination (i.e., anytime up until 25 
months).
Vaccine status information
Types of vaccines received were identified using individual Current Procedural Terminology 
(CPT) codes. Inactivated vaccines included DTaP, Hib, IPV, inactivated influenza vaccine 
(IIV), pneumococcal conjugate vaccine (PCV), HAV, and HBV. Live vaccines included 
MMR, varicella, and rotavirus, and live attenuated influenza vaccine (LAIV, licensed for 
ages 2–49 years). Because certain vaccines (e.g., inactivated: HAV and DTaP) may still be 
administered between the ages of 16 and 24 months, vaccination status was treated as a 
time-dependent exposure. The children’s vaccination status was defined as follows: 1) 
inactivated and live vaccines received on the same day; 2) live vaccines only; and 3) 
inactivated vaccines only. The first occurrence of vaccination status was the last vaccine 
received prior to 16 months, and if a vaccine was received between 16 months and 24 
months, their vaccination status changed accordingly on the date of vaccination.
Outcomes
For comparability, we assessed the same infectious conditions/outcomes evaluated by Sorup 
and colleagues3 (Supplementary Table). We evaluated up to 15 secondary discharge 
diagnoses, in addition to the primary diagnosis, for hospitalizations in all eligible children 
from age 16 through 24 months.
Statistical Analyses
To assess unadjusted rates of admissions per 100,000 person-years we counted the number 
of hospitalizations and number of person years according to most recent vaccine and use 
these numbers to calculate the unadjusted rates. For the adjusted analyses, we used extended 
Cox regression (which allows for time-dependent covariates and interactions with time for 
variables that do not meet the proportional hazards assumption) to estimate the hazard rate 
ratios (HRs), and 95% confidence intervals (CI). Age was the underlying time scale. In 
separate models, we assessed live only versus inactivated only, live only versus concurrent 
(live and inactivated), and concurrent versus inactivated only. We stratified by admission 
date for the newborn hospitalization (to control for age, seasonality and year) and adjusted 
for region, urban or rural metropolitan statistical area, mother’s age, low birth weight or 
prematurity (ICD-9 765.x for child, 644.20 and 644.21 for mother), number of previous 
hospitalizations prior to age 16 months (excluding hospitalization for birth), chronic 
conditions of the child (Supplementary Table 2),8 any previous hospitalization for NTI 
before 16 months of age, and number of outpatient visits before age 16 months. Based on 
previous studies,9 we evaluated sex as an effect modifier. Additionally, we assessed if any 
other factors modified the effect of type of vaccine received on risk of hospitalization. We 
assessed the risk of hospitalization until the child’s first hospital admission. Children were 
followed from the day they turned 16 months of age to hospitalization, or censorship due to 
disenrollment or turning 25 months of age.
We conducted sensitivity analyses which excluded vaccine preventable diseases (VPDs), 
such as pneumonia (potentially vaccine-preventable pneumonias, not all pneumonias), 
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hepatitis, pertussis, sepsis due to Haemophilus influenzae, and measles complicated by 
encephalitis or meningitis.
We also conducted secondary analyses for four groups of infections: upper respiratory 
infections (URI), lower respiratory infections (LRI), gastrointestinal infections (GI), and 
other infections.
Similar to the Danish study,3 we also evaluated emergency department visits for 
unintentional injuries (ICD-9 codes E800–E869 and E880–E929) as a control outcome using 
the same model as for the main analyses. We chose this event as a control outcome because 
it should not be causally associated with last type of vaccine received.10
The validity of the assumption of proportional hazards for all covariates was evaluated using 
Schoenfeld residuals. Violations of the proportionality assumption were identified for 
different variables across models. To account for these violations, we included interaction 
terms with time (where p < 0.05) for these terms in the models. Only vaccination status was 
modeled as a time-dependent variable in all the models. Joint multicollinearity was assessed 
using eigenvalues. This analysis involved only existing claims data, therefore Institutional 
Review Board review was not required.
Results
We identified a total of 687,022 infants with the code for newborn hospitalization who were 
enrolled within 31 days of birth and were continuously enrolled through 15 months of age, 
after excluding those on capitated plans (n=1,917). [Figure 1] After excluding those with 
immunosuppressive conditions (n=5,938) and those who received an influenza vaccine any 
time before 25 months of age (n=271,145) the sample included 409,939 children. Of these, 
342,659 (84%) received at least three doses of DTaP by 16 months and we could link 
311,663 (91%) to their mother’s information.
Of the 311,663 children included in the analyses, 51.3% were male, and 45% had claims 
indicating the last vaccine received prior to 16 months was inactivated only; for 16% the last 
vaccine received was live only; and 39% of the children received inactivated and live 
vaccines on the same day; 44.4% had a change in their vaccination status due to receipt of 
additional vaccines between 16 through 24 months of age [Figure 1]. Of those whose 
vaccine was live by 16 months, 88% received MMR-containing (i.e., MMR and MMRV) 
vaccines. Among those whose last vaccination status by 25 months was inactivated vaccine 
only, the majority (91.9%) had previously received MMR and/or varicella vaccine (81% 
received during the recommended age [i.e.12–15 months] and 19% after age 15 months). 
See supplement table A.
Children whose last vaccination status by 16 months was live vaccine only differed 
statistically from children whose last vaccination status was inactivated only or concurrent 
(live and inactivated) in that their mothers were older when they were born, they had more 
outpatient visits before 16 months, were more likely to be from the Northeastern US than the 
South or the West, and to live in urban areas (Table 1). Notably, there were no significant 
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differences in last vaccination status among children with chronic conditions or those who 
had low birthweight or were premature.
Infectious Disease Hospital Admission Risk
The most common NTI disease hospitalizations included pneumonia (33.0%) and ear 
infections (17.8%) (Supplemental Table B). Overall, the crude rate of hospital admissions 
for any NTI among children aged 16 through 24 months was 1,398 per 100,000 person-years 
(Table 2). The crude rate was higher among boys than girls. The overall crude risk of 
hospitalization for a NTI was 1,506 per 100,000 among those whose last vaccine type was 
live only compared with 1,317 per 100,000 among inactivated only and 1,599 per 100,000 
among concurrent receipt.
In the adjusted analyses, we found statistically significant decreases in the risk of 
hospitalization for NTI diseases when the last type of vaccine received included a live 
vaccine. In the overall Cox regression model, compared with those whose last vaccine was 
inactivated only, the hazard ratio (HR) for those who received a live vaccine was 0.50; 95% 
CI: 0.43, 0.57. (Table 2) This finding was also consistent for boys and for girls. Similarly, 
for those whose last vaccine was live only compared with concurrent receipt of live and 
inactivated vaccines the overall HR was 0.78 (95% CI: 0.67, 0.91), and was also 
significantly reduced among boys and girls. The adjusted analyses found statistically 
significant reduced risks of NTI hospitalization for concurrent vaccines compared with 
inactivated. No factors were found to have statistically significant interaction with last 
vaccine type received.
Sensitivity analyses and control outcome
In the secondary analyses that excluded VPDs (Table 3), the adjusted risk of hospitalization 
scarcely changed from the results of the models including VPDs. In the four models that 
evaluated NTI hospitalization risks for different categories of infections, the adjusted risk for 
upper and lower respiratory infections was lower for those whose last vaccine type included 
a live vaccine compared with inactivated only (Table 4). Risk of hospitalization was lower 
for other viral and bacterial infections among those whose last vaccine type received was 
live only compared with inactivated only (Table 5). We also performed the analyses to assess 
variation between regions but did not find an association. (Supplemental Table C).
Results of the control outcome, unintentional injuries, were not significantly associated with 
type of last vaccine received. The risk of an emergency room visit for an unintentional injury 
from 16 through 24 months of age was not different if the type of last vaccine received was 
live only compared with inactivated only (HR: 1.16, 95% CI: 0.90, 1.48) or compared with 
concurrent vaccines (HR: 1.09 95% CI: 0.83, 1.43). No difference was found comparing 
concurrent receipt with inactivated vaccine.
Discussion
We found a significantly lower risk of NTI hospitalization for children aged 16 through 24 
months if the last type of vaccine they received was live only compared with receipt of 
inactivated only vaccines. A similar but less pronounced decreased risk was found if the type 
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of last vaccine received was concurrent (live and inactivated) vaccines compared with 
inactivated only vaccine. These findings were similar for boys and girls. The results of our 
secondary analyses that excluded hospitalizations for vaccine preventable diseases were not 
materially different. Thus, our study tends to support the overall findings of the Danish 
study3. Additionally, we found that the reduced risk of NTI hospitalization when the last 
type vaccine was live only was strongest for lower and upper respiratory infections.
Like the Danish study3, we also assessed the risk of hospitalization including VPDs and 
their complications in the outcomes. Since their inclusion mixes non-specific with specific 
(targeted) outcomes and could result in apparently stronger associations through the 
prevention of targeted outcomes, we excluded VPDs from secondary analyses. However, our 
results changed only minimally.
Importantly, our study extends the earlier findings of Sørup and colleagues because we 
evaluated the more comprehensive US childhood vaccination schedule, which includes 
several vaccines not included in the Danish childhood vaccination schedule. For example, 
the Danish study specifically evaluated MMR vs. DTaP-IPV-Hib as the last vaccine received, 
whereas we assessed receipt of any live vaccine (i.e., MMR or Varicella) and any inactivated 
vaccine (DTaP, Hib, IPV, PCV, HAV, and HBV) so our analyses extend support for non-
specific effects by type of vaccine rather than only by specific vaccines. Also, since children 
who received influenza vaccine (IIV or LAIV) may be at different risk for respiratory 
infections, to be consistent with the Danish study, we excluded children who ever received 
an influenza vaccine during the study.
The 2014 Danish study3 did not assess concurrent receipt of live and inactivated vaccines, 
but another study by the same authors published in 2016 found simultaneous administration 
of MMR and DTaP-IPV-Hib compared with MMR alone may increase the rate of hospital 
admissions related to lower respiratory tract infections.11 Similarly, we found that receipt of 
live vaccine alone had a lower risk compared with inactivated alone or concurrent and that 
concurrent had a lower risk compared with inactivated. This suggests that the decreased risk 
found when a live vaccine was received alone was diluted but still present when concurrent 
(live and inactivated) vaccines were received compared with inactivated vaccine only.
A limitation of our study is that data on potential confounders such as the children’s race 
and/or ethnicity and socio-economic status were not available. Although race and/or 
ethnicity could not be inferred from Marketscan®, socio-economic status could be partially 
inferred because all the children in the database were covered by commercial health 
insurance plans in which the family’s health insurance was provided through an employer of 
a family member. Also, our analysis was limited in that we were unable to conduct medical 
chart reviews to ensure the validity of the ICD-9 codes specified in the hospitalization 
inpatient claims and the CPT codes for vaccinations in the outpatient claims.
Distinctly, the children included in our analyses had received at least 3 doses of DTaP, an 
indication that they were a vaccinated group, so we were not comparing vaccinated to 
unvaccinated, and therefore they differed only on the type(s) of vaccine received last. The 
vast majority (91.9%) of the children whose last vaccine received was inactivated by the end 
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of the study had previously received the MMR and/or varicella vaccines; most received the 
vaccine when recommended, yet 19% received the vaccine after the recommended age of 15 
months but before they received an inactivated vaccine just prior to study-end; therefore it 
may be that our results are affected by selection bias if the healthiest children received MMR 
and/or varicella vaccine by 15 months, and received the last dose of DTaP later12. However, 
if that were the case the results should be the same for all infections, yet, like the Danish 
study,3 our results were strongest for respiratory infections. Also, there was no significant 
difference in the proportion of children with chronic conditions, low birth weight or 
prematurity receiving live or inactivated vaccines last. Moreover, in the sensitivity analyses, 
receipt of live vaccine last was not associated with a lower risk of unintentional injury, 
which implies that our results are not an effect of health-seeking bias. Lastly, another 
potential concern is misclassification bias if the 8.1% of children who did not have claims 
for MMR and/or varicella vaccines actually did receive one or both of them; for example, 
through an immunization provider not participating in MarketScan®. There is no way to 
know the direction of the potential misclassification with respect to the outcome.
Notably, the hazard ratios in our analyses were less than 1 yet some of the unadjusted rates 
of NTI hospitalizations per 100,000 person-years were in the opposite direction. The 
confounding variables that impacted the adjusted results included mother’s age, region, and 
number of outpatient visits. Inclusion of number of outpatient visits had the strongest effect 
on the adjusted hazard ratios. It is not unexpected that number of prior outpatient visits 
would influence the risk of NTI hospitalization, but we do not know why number of 
outpatient visits would also be strongly associated with receiving a live vaccine only as the 
last vaccine.
Possible biologic mechanisms to support our findings have not been identified, but could 
include the concept of ‘heterologous immunity.’ That is, each person has a unique history of 
infections and vaccinations and every exposure leaves an imprint on the immune system that 
can affect future immune (innate and adaptive) responses to pathogens.13 Additionally, 
studies have shown that innate immune responses have adaptive traits that have the potential 
to provide protection against unrelated infections, a process called ‘trained immunity.’14 A 
review by IOM in 2002 concluded that “…there is strong evidence for the existence of 
biological mechanisms by which multiple immunizations under the current U.S. infant 
immunization schedule could possibly influence an individual’s risk for heterologous 
infections.”15
Our study addresses a topic of current interest as evidenced by the review being conducted 
by the World Health Organization Strategic Advisory Group of Experts who are currently 
reviewing all available evidence on nonspecific vaccine effects to determine if immunization 
policy adjustments are needed.16,17,18
Along with other recent studies, our study raises the possibility that the order in which 
vaccines are administered may carry benefits in addition to the prevention of the targeted 
infections. But the interpretation of our results should be tempered because the extent of 
potential biases from confounding and selection bias is unknown. To further improve the 
quality of the evidence on this topic, future studies should include chart reviews to ensure 
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the validity of the ICD codes for the outcomes of interest and to use well-validated databases 
or registries to ensure correct identification of vaccination status. Ideally, randomized control 
trials would best control for confounding and avoid selection bias.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Summary
We found a significantly lower risk of non-targeted infectious disease hospitalization for 
children aged 16 through 24 months if the last type of vaccine they received prior to 
hospitalization was live only compared with receipt of inactivated only vaccines.
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Figure 1. 
Flowchart of Study Inclusion
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